title: The use of ultra-dense array CGH analysis for the discovery of micro-copy number alterations and gene fusions in the cancer genome.
abstract: BACKGROUND
  Molecular alterations critical to development of cancer include mutations, copy number alterations (amplifications and deletions) as well as genomic rearrangements resulting in gene fusions. Massively parallel next generation sequencing, which enables the discovery of such changes, uses considerable quantities of genomic DNA (> 5 ug), a serious limitation in ever smaller clinical samples. However, a commonly available microarray platforms such as array comparative genomic hybridization (array CGH) allows the characterization of gene copy number at a single gene resolution using much smaller amounts of genomic DNA. In this study we evaluate the sensitivity of ultra-dense array CGH platforms developed by Agilent, especially that of the 1 million probe array (1 M array), and their application when whole genome amplification is required because of limited sample quantities.
  
  
  METHODS
  We performed array CGH on whole genome amplified and not amplified genomic DNA from MCF-7 breast cancer cells, using 244 K and 1 M Agilent arrays. The ADM-2 algorithm was used to identify micro-copy number alterations that measured less than 1 Mb in genomic length.
  
  
  RESULTS
  DNA from MCF-7 breast cancer cells was analyzed for micro-copy number alterations, defined as measuring less than 1 Mb in genomic length. The 4-fold extra resolution of the 1 M array platform relative to the less dense 244 K array platform, led to the improved detection of copy number variations (CNVs) and micro-CNAs. The identification of intra-genic breakpoints in areas of DNA copy number gain signaled the possible presence of gene fusion events. However, the ultra-dense platforms, especially the densest 1 M array, detect artifacts inherent to whole genome amplification and should be used only with non-amplified DNA samples.
  
  
  CONCLUSIONS
  This is a first report using 1 M array CGH for the discovery of cancer genes and biomarkers. We show the remarkable capacity of this technology to discover CNVs, micro-copy number alterations and even gene fusions. However, these platforms require excellent genomic DNA quality and do not tolerate relatively small imperfections related to the whole genome amplification.
authors.affiliation: Department of Oncology, Lady Davis Institute, Sir Mortimer B, Davis Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
authors.forename: Ewa
authors.initials: E
authors.lastname: Przybytkowski
authors.forename: Cristiano
authors.initials: C
authors.lastname: Ferrario
authors.forename: Mark
authors.initials: M
authors.lastname: Basik
mesh_terms: D000465:Algorithms; D001943:Breast Neoplasms / Q000235:genetics; D045744:Cell Line, Tumor; D055028:Comparative Genomic Hybridization / Q000379:methods*; D004247:DNA / Q000235:genetics; D056915:DNA Copy Number Variations / Q000235:genetics*; D018076:DNA, Complementary / Q000235:genetics; D005260:Female; D018628:Gene Dosage; D050939:Gene Fusion; D016678:Genome; D006801:Humans; D009369:Neoplasms / Q000235:genetics
chemical_list: D018076:DNA, Complementary; D004247:DNA